So far, results from clinical trials of GBM patients are available for CAR-T cells targeting three antigens: EGFRvIII, IL-13 receptor alpha 2(IL-13Rα2), and human epidermal growth factor receptor 2 (HER2) (141–144). This evidence concerns the gene ERBB2 and glioblastoma.